Active Steroid 5 Alpha Reductase 2 (SRD5a2) Homo sapiens (Human) Active protein

3-Oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 2

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point8.7
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Steroid 5 Alpha Reductase 2 (SRD5a2) Packages (Simulation)
  • Active Steroid 5 Alpha Reductase 2 (SRD5a2) Packages (Simulation)
  • APM285Hu03.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Steroid 5 Alpha Reductase 2 (SRD5a2) is a microsomal enzyme critical in steroid metabolism, primarily converting testosterone to dihydrotestosterone (DHT), a potent androgen. Expressed in androgen-sensitive tissues (e.g., prostate, skin), it regulates male sexual development, hair growth, and prostate function. Additionally, the SRD5a2-CYP17A1 complex optimizes androgen synthesis: CYP17A1 generates testosterone precursors, while SRD5a2 amplifies androgen potency via DHT production. This collaboration ensures efficient testosterone utilization and targeted DHT formation, critical for physiological androgen effects and pathological conditions.Thus a functional ELISA assay was conducted to detect the interaction of recombinant human SRD5a2 and recombinant human CYP17A1. Briefly, CYP17A1 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to SRD5a2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-CYP17A1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. Measured by its binding ability in a functional ELISA. When recombinant SRD5a2 is lmmobilized at 2 ug/mL(100 uLwell), the concentration of CYP17A1 that produces 50% optimal bindingresponse is found to be approximately 0.307 ug/mL.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Seoritae extract reduces prostate weight and suppresses prostate cell proliferation in a rat model of benign prostate hyperplasiaPubmed:24701239
  • TSPO activation modulates the effects of high pressure in a rat ex vivo glaucoma model.pubmed:27596950
  • Effects of ethanolic extracts of Cola millenii K. Schum seed on biochemical and toxicological indices of male wistar albino rats1616357
  • Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats10.4162:nrp.2018.12.e36
  • Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 234265299

Recommend products